Ann Dermatol.  2013 Nov;25(4):504-505. 10.5021/ad.2013.25.4.504.

Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response

• Urun Y
• Utkan G

• KMID: 2265075
• DOI: http://doi.org/10.5021/ad.2013.25.4.504

Abstract

No abstract available.

MeSH Terms

Antibodies, Monoclonal, Humanized
Humans
Rectum*
Cetuximab
Antibodies, Monoclonal, Humanized

Figure

• 

  Fig. 1 Eyelash elongation after cetuximab treatment (published with permission of patient).

• 

  Fig. 2 Patient's second photograph after reintroduction of cetuximab (published with permission of patient).

Reference

1. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010; 36:550–556.

2. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19:508–515.

3. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010; 24:453–459.

4. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007; 6:175–182.

5. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16:1425–1433.